Genentech, Inc.

F. Hoffmann-la Roche Ag

Xenon Pharmaceuticals Inc.

Curis, Inc.

Hoffmann-la Roche Inc.

Piramed Limited

Genetech, Inc.

Daniel P Sutherlin

Georgette M Castanedo

Alan G Olivero

Adrian Folkes

Brian Salvatore Safina

Bing-Yan Zhu

Richard A Goldsmith

Tim Heffron

Irina Chuckowree

Nan Chi Wan

Shumei Wang

Janet Gunzner

Christoph Martin Dehnhardt

Sultan Chowdhury

Steven T Staben

Ivan William Hemeon

Simon Mathieu

Tracy Bayliss

Thilo Focken

Michael Edward Grimwood

Sally Oxenford

Kimberly Malesky

Mark E Reynolds

Mark S Stanley

Zachary Kevin Sweeney

Shaoyi Sun

Daniel Fred Ortwine

Qi Jia

Alla Yurevna Zenova

Steven McKerrall

Michael S Dina

Eileen Mary Seward

Matthew C Lucas

Dean R Artis

David Y Jackson

Thomas E Rawson

Jun M Li

Jennafer Dotson

Zhiguo Liu

Stephen Colin Price

Bryan K Chan

Steven Huy Do

Aleksandr Kolesnikov

Michael Siu

Michael Scott Wilson

Kwong Wah Lai

Scott J Savage

Pascal Pierre Alexandre Savy

Liang Bao

Rebecca L Lalonde

Kirk D Robarge

Vickie H Tsui

Jean-Christophe Andrez

John A Flygare

Robert Andrew Heald

Christian Wiesmann

Timothy Heffron

Yan Zhu

Claudio F Sturino

Richard Pastor

Aihe Zhou

Tao Wang

Mark A Reynolds

BinQing Wei

Frederick Cohen

Birong Zhang

Wayne J Fairbrother

Emanuela Gancia

Binqing Wei

Michael F T Koehler

Paul Goldsmith

Neil Pegg

Jiuxiang Zhu

Shannon Marie Decker

Tao Sheng

David Goldstein

Rama Kondru

Wylie Palmer

Andrew D White

Stephen Joseph Shuttleworth

Janet L Gunzner-Toste

Philippe Bergeron

Paul Robert Bichler

Ramsay Beveridge

Tim Hancox

Abid Hasan

Jean-Philippe Leclerc

Bohdan Waszkowycz

Ignacio Aliagas-Martin

Stephen Shuttleworth

Alexandre Lemire

Liang Zhao

Chien-An Chen

Frederick C Sailes

Regina A Munroe

Richard Leonard Elliott

Kristen Nicole Burford

Wei Gong

Wenfeng Liu

Scott Savage

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R, R, subscript n, ring A, X, L, subscript m, X, ring B, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Substituted benzamides and methods of use thereof

The invention provides compounds having the general formula I:  and pharmaceutically acceptable salts thereof, wherein the variables R, n, ring A, X, L, m, X, R, R, R, R, X, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Therapeutic compounds and methods of use thereof

The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain. The following compound is illustrative: 

The invention provides 4-piperidin-chroman-7-sulfonamide derivatives and salts thereof that are sodium channel modulators, as well as compositions containing such a compound or salt and therapeutic methods for using such a compound, salt, or composition.

4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors

The invention provides a compound of formula: or a salt thereof, wherein the variables R, n, ring A, ring B, R, R, R, R, R, R, R, R, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I: (i) and pharmaceutically acceptable salts thereof, wherein the variables R, R, subscript n, ring A, X, L, subscript m, X, ring B, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. 

The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y&#x2014;Y, R, R, R, R, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X, L, subscript m, X, ring D, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. 

N-substituted benzamides and methods of use thereof

Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pharmaceutical compounds

The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R, R, R, R, m and n are as described herein.

Pyridyl inhibitors of hedgehog signalling

The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables R, subscript n, ring A, X, L, subscript m, X, B, R, R, R, R, Rand Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R, R, subscript n, ring A, X, L, subscript m, X, R, R, R, R, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and Ris a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Phosphoinositide 3-kinase inhibitor compounds and methods of use

Growing community of inventors

San Carlos, CA, United States of America

Daniel P Sutherlin